BioSpace News Archive

Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company specialising in the treatment of Alzheimer’s disease by specifically targeting neurotoxic amyloid-beta oligomers, announced today that the company has received approval from the regulatory authorities in Finland to initiate the first clinical study with the vaccine candidate, ALZ-101.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), candidate DM199 for the treatment of acute ischemic stroke (AIS) where tissue plasminogen activator and/or mechanical thrombectomy are not indicated or medically appropriate.

Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that it has initiated a Phase 1 study for ATRS-1902 for adrenal crisis rescue.

As part of its RAPID-DxTM (Research Alliance for Precision Therapeutics, Innovation and Diagnostics) program, researchers from Cohen Veterans Bioscience (CVB) and collaborators conducted a blinded cross-platform analysis (or “bakeoff”) of commercially available assay platforms to inform selection in the conduct of neuropsychiatric biomarker research.

Currax Pharmaceuticals, LLC (“Currax”), a specialty biopharmaceutical company dedicated to expanding access to clinically differentiated, underappreciated medicines – both branded and generic – hosted a grand opening celebration of its new headquarters on September 29, 2021.

UltraSight, a digital health pioneer transforming cardiac imaging through the power of AI, announced a new collaboration with GE Healthcare to conduct a cardiac study aboard the Axiom ‘Rakia’ space mission, and the successful completion of Preliminary Design Review (PDR) for Cardiac Point of Care Ultrasound (POCUS).

RaySearch Laboratories AB announces that Centre hospitalier universitaire vaudois in Lausanne, Switzerland, is the first center in the world to treat a patient using the RayStation®* treatment planning system in combination with Accuray CyberKnife® treatment delivery system.

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® AAV9 Titer Kit for rapid determination of physical titer in adeno-associated virus serotype 9 (AAV9) vector-based cell and gene therapy manufacturing.

Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 4, 2021. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2021 financial results and respond to questions from financial analysts during the call.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), announces that greater than 50% of patients expected to complete the ONWARD™ Phase 3 trial evaluating AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes have completed the full, 24-week, treatment period.